Looking for an Alternative to Mounjaro for Diabetes?

The misconception worth clearing up first

There's a fairly common assumption that if Mounjaro isn't an option, the next step is simply to find something "similar", another injection, another GLP-1, maybe Ozempic. That's understandable. But it isn't quite how diabetes prescribing works, and holding that assumption can lead people toward medicines that aren't licensed for the right purpose, or that aren't the best clinical fit for them personally.

Ozempic is semaglutide. It acts on GLP-1 receptors and lowers blood glucose, and it is indeed licensed for type 2 diabetes in the UK. But it's licensed specifically for diabetes, not for weight management, so if weight loss is a separate goal, that matters to the prescribing conversation. Wegovy is also semaglutide, licensed for weight management, and a prescriber considering both diabetes and weight in your case needs to think about which licence applies and why. The clinical role of Mounjaro in diabetes management is worth understanding before assuming any replacement will do the same job.

The gentler version of this: it's less about finding the nearest lookalike, and more about what your prescriber thinks is most appropriate given your HbA1c, your other medicines, your kidney function, and your cardiovascular risk. Let go of the idea that one drug is automatically interchangeable with another, and the conversation with your clinician becomes much more productive.

Which alternatives are actually used in UK type 2 diabetes care?

The UK diabetes landscape offers several licensed classes your prescriber can draw from, depending on where you are in your treatment journey. The NHS medicines page for tirzepatide is a useful reference point for understanding what makes it distinct, and by contrast, what alternatives offer.

Other GLP-1 receptor agonists. Semaglutide (Ozempic, weekly injection), liraglutide (Victoza, daily injection), and dulaglutide (Trulicity, weekly injection) are all licensed for type 2 diabetes in the UK. They share a broadly similar mechanism to one component of Mounjaro's dual action. Average weight and glucose outcomes vary between them, and tolerability differs person to person.

SGLT-2 inhibitors. Medicines like empagliflozin, dapagliflozin and canagliflozin work by causing the kidneys to excrete glucose in urine. They have established cardiovascular and renal protective benefits, which makes them particularly relevant for people with heart or kidney disease alongside type 2 diabetes. NICE guidance includes them in its treatment pathways.

DPP-4 inhibitors. Sitagliptin, saxagliptin and others in this class are generally well tolerated and weight-neutral. They're often used where GLP-1 agonists aren't tolerated or aren't appropriate. Effect on HbA1c tends to be more modest.

Insulin. For people whose diabetes isn't controlled by oral or injectable non-insulin medicines, insulin remains a cornerstone. There are many types and regimens; your diabetes team or GP will guide you.

The NICE guideline on type 2 diabetes in adults sets out how these classes fit together in a stepped treatment pathway, and a question our prescribers hear regularly is why one class is prioritised over another. The answer is almost always individual rather than universal.

When Mounjaro is stopped or unavailable, what happens to blood glucose?

Tirzepatide actively lowers blood glucose as well as supporting weight loss. If it's stopped abruptly, blood sugar levels can rise, sometimes substantially. This is a clinically important point that doesn't always get enough attention. Your prescriber will want to plan a transition rather than simply discontinuing, and if you've been on Mounjaro for type 2 diabetes rather than a formal weight management programme, the implications may differ again.

Supply disruptions have affected GLP-1 medicines before, and they may again. If you're in this situation, the right call is to contact your prescriber or GP promptly rather than waiting to see what happens to your readings. You can read more about how tirzepatide performs in type 2 diabetes to understand what you may be losing from a glycaemic perspective when a switch is made.

Your GP's records, and any shared care notes from a specialist, will inform what an appropriate bridge treatment looks like. Don't bridge across to another prescription medicine without that conversation.

Practical next steps if you're considering a switch

Speak to your prescriber before changing anything. That sounds obvious, but it bears saying plainly: adjusting or stopping a diabetes medicine is a clinical decision, not something to navigate alone based on what's available online. The range of contexts in which tirzepatide is used for diabetes is broader than many patients realise, and your prescriber may have options you haven't considered.

If you've been accessing tirzepatide privately for weight management and also have type 2 diabetes, there's an added layer of complexity, and it's also worth reading up on whether you can drink on Mounjaro so you have a full picture of lifestyle factors to discuss with your clinician. A GPhC-registered Independent Prescriber reviews every consultation at nume (a real clinician reads your answers, not software) and can discuss whether continuing, pausing or transitioning is appropriate in your situation. For any questions specific to your diabetes management, your GP or diabetes team should be your primary point of contact.

If you'd like to understand more about treatment options for weight loss, our free consultation is a good place to start. You can also browse our treatment overview to see what's currently available through nume. For questions about individual circumstances, our team is available seven days a week.